On Oct. 4, 2021, Dynavax Technologies and the U.S. Department of Defense (DOD) announced Dynavax had executed an agreement for approximately $22 million over two and a half years to develop a recombinant plague vaccine adjuvanted with CpG 1018ﾮ.